✦ LIBER ✦

PCV50 COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

✍ Scribed by Y. Zhao; L. Lim; C.I. Coleman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV53 A Cost-Effectiveness Analysis Comp

✍ M. Psenkova; S. Mackovicova; D. Tomek; J. Bielik; H. Spitzerova 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCV54 Cost-Effectiveness Analysis of Dab

✍ M.A. Ward; A.K. Biddle 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCV57 Cost-Effectiveness of Rivaroxaban

✍ A.K. Kapur; I. Chatzitheofilou; L.K. Schang 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Cost–Effectiveness of Rivaroxaban Compar

✍ Soyon Lee; Moise W. Anglade; Dan Pham; Robyn Pisacane; Jeffrey Kluger; Craig I. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 786 KB

PMD10 Analysis of Costs of Complications

✍ S. Armstrong; S. Amorosi; R. Peppa; L. Da Deppo; S. Garfield 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost-effectiveness of apixaban vs warfar

✍ Kamel, H.; Easton, J. D.; Johnston, S. C.; Kim, A. S. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 578 KB